Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268407 | 0.78 | KCNH3 (0.43) | TLR8 | |
| SCHEMBL13313183 | 0.77 | KDM4E (0.46) | CYP1A2CYP2C19MEN1KMT2AKDM4E | |
| SCHEMBL13271036 | 0.70 | PLAU (0.46) | CYP1A2CYP2C19SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19622955 | 0.70 | CA12 (0.46) | CA12CA2CA9CYP1A2CYP2C19 | |
| SCHEMBL10377418 | 0.68 | HRH4 (0.48) | CYP1A2CYP2D6CYP2C19HRH4HRH3 | |
| SCHEMBL11604740 | 0.67 | CA12 (0.82) | CA12CA2CA9CYP2D6KDM4E | |
| SCHEMBL11122843 | 0.66 | CA12 (0.83) | CA12CA2CA9CYP2D6KDM4E | |
| SCHEMBL11119051 | 0.66 | CA12 (0.83) | CA12CA2CA9CYP2D6KDM4E | |
| SCHEMBL11118157 | 0.66 | CA12 (0.83) | CA12CA2CA9CYP2D6KDM4E | |
| SCHEMBL5935029 | 0.66 | CA12 (0.83) | CA12CA2CA9CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210892-A2 | Neurologically-active compounds | Prana Biotechnology Limited (AU) | 2010-07-28 | — | — | EP | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| EP-1558585-A4 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2008-07-02 | — | — | EP | disclosed |
| US-20060167000-A1 | Neurologically-active compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167000-A1 | Neurologically-active compounds | ACHE, PSEN1, PSEN2 | CA12 1970/4885CA2 1501/4885CA9 1744/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | CA12 2074/4885CA2 1403/4885CA9 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.